Can a diabetes drug help dialysis patients manage fluid buildup?
NCT ID NCT05786443
First seen Dec 04, 2025 · Last updated Jun 18, 2026 · Updated 21 times
Summary
This study tests whether empagliflozin, a diabetes medicine, is safe and helps control body fluid levels in 60 adults who are starting hemodialysis for end-stage kidney disease. Participants will take either empagliflozin or a placebo for 12 weeks. The goal is to see if the drug improves fluid balance and blood pressure without causing harm.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 021215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.